Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

Autor:	Takashi Kobayashi, Shintaro Kanda, Toshirou Fukushima, Takuro Noguchi, Nodoka Sekiguchi, Tomonobu Koizumi
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	1151Tins ALK gynecological metastasis lorlatinib non‐small cell lung cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Thoracic Cancer, Vol 12, Iss 16, Pp 2275-2278 (2021)
Druh dokumentu:	article
ISSN:	1759-7714 1759-7706
DOI:	10.1111/1759-7714.14056
Popis:	Abstract We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizotinib and alectinib resistance mutation. Subsequent therapy with the third‐generation ALK inhibitor lorlatinib, but not ceritinib, showed antitumor activity for 1 year. The uterus is an uncommon site for metastasis from lung cancer, and our case indicated that serial gene analysis could provide new information about ALK inhibitor resistance.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/4797ef09b86e4644a2254d2f7defc5be Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF